Clinical trial
Gleevec Combined With Camptosar Plus Paraplatin in Previously Untreated…
NCT00193349 · SCRI Development Innovations, LLC, Other · Completed
Key facts
| NCT number | NCT00193349 |
|---|---|
| Title | Gleevec Combined With Camptosar Plus Paraplatin in Previously Untreated Extensive Stage Small Cell Lung Cancer |
| Official title | Phase II Evaluation of Gleevec Combined With Camptosar Plus Paraplatin in Patients With Previously Untreated Extensive Stage SCLC |
| Lead sponsor | SCRI Development Innovations, LLC, Other |
| Collaborators | Novartis Industry Pharmacia and Upjohn |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lung Cancer |
| Intervention type | Drug |
| Interventions | Imatinib, Irinotecan, Carboplatin |
| Enrollment | 60 |
| Start date | Sep 1, 2002 |
| Primary completion | Dec 1, 2007 |
| Completion | Dec 1, 2007 |
| First posted | Sep 19, 2005 |
| Last update posted | Jun 28, 2010 |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: